检索结果-南通市图书馆

Neuroscience Bulletin 2019年第2期35卷 216-224页

作者： Yu Sun Cheng Xu Changcun Pan Xin Chen Yibo Geng Yuliang Wu Peng Zhang Wenhao Wu Yu Wang Deling Li Zhen Wu Junting Zhang Qiaoran Xi Liwei Zhang Department of Neurosurgery Beijing Tiantan HospitalCapital Medical University Ministry of Education Key Laboratory of Protein Sciences School of Life Sciences Tsinghua University

diffuse intrinsic pontine glioma(DIPG) is the main cause of brain tumor-related death among children.Until now, there is still a lack of effective therapy with prolonged overall survival for this disease. A typical strategy for preclinical cancer research is to find out the molecular differences between tumor tissue and para-tumor normal tissue, in order to identify potential therapeutic targets. Unfortunately, it is impossible to obtain normal tissue for DIPG because of the vital functions of the pons.Here we report the human fetal hindbrain-derived neural progenitor cells(pontine progenitor cells, PPCs) as normal control cells for DIPG. The PPCs not only harbored similar cell biological and molecular signatures as DIPG glioma stem cells, but also had the potential to be immortalized by the DIPG-specific mutation H3 K27 M in vitro. These findings provide researchers with a candidate normal control and a potential medicine carrier for preclinical research on DIPG.

关键词： diffuse intrinsic pontine glioma Neural progenitor cells Immortalization H3K27M Senescence

diffuse large B-cell lymphoma arising from follicular lymphoma with warthin’s tumor of the parotid gland-immunophenotypic and genetic features: A case report

在线全文

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2019年第22期7卷 3895-3903页

作者： Chang-Song Wang Xia Chu Di Yang Lei Ren Nian-Long Meng Xue-Xia Lv Tian Yun Yan-Sha Cao Department of Pathology 989th Hospital of PLALuoyang 471000Henan ProvinceChina Department of Pathology 988^th Hospital of PLAZhengzhou 450042Henan ProvinceChina Department of Pathology Sanmenxia center HospitalSanmenxia 472000Henan ProvinceChina Department of Pathology Luoyang First People’s HospitalLuoyang 471000Henan ProvinceChina

BACKGROUND Warthin’s tumor(WT)is composed of several cysts that are lined with tall,bilayered oncocytic columnar cells and lymphoid stroma.Within WT,the two components rarely transform into carcinoma or lymphoma,and when it does,carcinoma is the most common type.Approximately 28 cases of lymphoma with WT have been reported,most of which were non-Hodgkin lymphomas,and only a few cases were Hodgkin lymphomas.In the present report,we studied a case of diffuse large B cell lymphoma(DLBCL)arising from follicular lymphoma(FL)with WT in the parotid gland and its immunophenotypic and genetic features.CASE SUMMARY A 67-year-old man presented with a slowly enlarging right cheek mass for 12 years,and the mass began to change in size over a 2-mo time period.Over time,the patient felt mild local pain and right cheek discomfort.His medical history included a hepatitis B virus infection for 20 years and 30 years of smoking.Gross examination of the excised specimen showed a gray-red and gray-white appearance and a soft texture lobulated external surface neoplasm that measured 9 cm×8 cm×7 cm and was well circumscribed by relative normal parotid gland tissue.In cross section,the cut surfaces of the neoplasm were multicystic and had a homogeneous scaly appearance.A small fluid was discovered in the cyst.Bilateral oxyphilic,cuboidal or polygonal epithelium cells and lymphoid intraparenchymal components were observed.Many medium-to large-sized lymphoid cells were observed diffusely in part of the neoplasm,and a few secondary lymphoid follicles were observed at the center or edge of the neoplasm.Immunohistochemical staining showed that the columnar oncocytic cells were positive for AE1/AE3;neoplastic cells located in coarctate follicular were positive for CD20,Pax-5,bcl-2 and bcl-6;and the adjacent diffusely medium-to large-sized lymphoid cells were positive for Pax-5,bcl-6,CD20,MUM-1,bcl-2 and CD79a.The bcl-6(3q27)break-apart rearrangement was observed,and an Epstein Barr virus test was negative in the tumor cells.The patient survive

关键词： diffuse large B cell lymphoma Warthin’s tumor Parotid gland Follicularlymphoma Case report Genetic feature

diffuse interstellar absorption bands

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Science China(Physics,Mechanics & Astronomy) 2009年第4期52卷 489-501页

作者： XIANG FuYuan1,2,LIANG ShunLin2 & LI AiGen2,3 1 Faculty of Materials,Photoelectronics and Physics,Xiangtan University,Xiangtan 411105,China 2 Department of Physics and Astronomy,University of Missouri,Columbia,MO 65211,USA 3 Purple Mountain Observatory,Chinese Academy of Sciences,Nanjing 210008,China Faculty of Materials Photoelectronics and Physics Xiangtan University Xiangtan China Department of Physics and Astronomy University of Missouri Columbia USA Purple Mountain Observatory Chinese Academy of Sciences Nanjing China

The diffuse interstellar bands(DIBs) are a large number of absorption bands that are superposed on the interstellar extinction curve and are of interstellar origin. Since the discovery of the first two DIBs in the 1920s,the exact nature of DIBs still remains unclear. This article reviews the history of the detections of DIBs in the Milky Way and external galaxies,the major observational characteristics of DIBs,the correlations or anti-correlations among DIBs or between DIBs and other interstellar features(e.g. the prominent 2175 Angstrom extinction bump and the far-ultraviolet extinction rise),and the proposed candidate carriers. Whether they are also present in circumstellar environments is also discussed.

关键词： astrophysics interstellar matter interstellar extinction diffuse interstellar band circumstellar environment

A retrospective analysis of real-world outcomes of elderly Chinese patients with diffuse large B-cell lymphoma

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2019年第15期132卷 1807-1814页

作者： Peng Liu Ying Han Shi-Yu Jiang Xiao-Hui He Yan Qin Lin Gui Sheng-Yu Zhou Li-Qiang Zhou Jian-Liang Yang Sheng Yang Ting-Yu Wen Yuan-Kai Shi Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs Beijing 100021 China

Background:Elderly patents with diffuse large B-cell lymphoma (DLBCL) have a worse prognosis than younger patients,and the optimal treatment strategy for this group remains controversial.We conducted a retrospective analysis to investigate the clinical features and outcomes of elderly patients (>60 years) and to assess the impact of clinical and molecular factors on outcome in this age group.Methods:From April 2006 to December 2012,a total of 349 elderly patients with DLBCL from the National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences,and Peking Union Medical College were included in this analysis.Patients were further divided into two age groups (61-69 years and ≥70 years).We compared clinical characteristics and outcomes between groups.Results:Of 349 total patients,204 (58.5%) were aged 61 to 69 years,and 145 (41.5%) patients were aged 70 years or older.Except for the Eastern Cooperative Oncology Group performance status,clinical characteristics were comparable between the two groups.With a median follow-up of 82 (range,1-129) months,the 5-year overall survival (OS) and progression-free survival (PFS) rates were 51.9% and 45.8%,respectively.The 5-year OS rates for patients aged 61 to 69 years and those over 70 years were 58.3% and 42.8%(P =0.007),respectively,and the 5-year PFS rates were 51.0% and 38.6%(P =0.034).Treatment regimens including rituximab provided a higher 5-year OS rate (63.1% vs.37.1%,P < 0.001) and PFS rate (56.6% vs.31.8%,P < 0.001) than chemotherapy alone.For patients aged 61 to 69 years,chemotherapy plus rituximab resulted in a higher 5-year OS rate (66.7% vs.46.4%,P =0.002) and PFS rate (60.0% vs.38.1%,P =0.002) than chemotherapy alone.For patients aged ≥70 years,there was a marked survival advantage in patients who received chemotherapy plus rituximab (5-year OS rate:57.7% vs.25.4%,P < 0.001;5-year PFS rate:51.3% vs.23.9%,P < 0.001) compared with that seen in those who received chemotherapy alone.Multivariate analysis established that stage Ⅲ/Ⅳ disease,elevated lactat

关键词： Elderly diffuse large B-cell lymphoma Rituximab Prognosis

Prognostic value of interim ^(18)F-FDG PET/CT in diffuse large B-cell lymphoma

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2013年第1期25卷 95-101页

作者： Zhitao Ying Xuejuan Wang Yuqin Song Wen Zheng Xiaopei Wang Yan Xie Ningjing Lin Meifeng Tu Lingyan Ping Weiping Liu Lijuan Deng Chen Zhang Zhi Yang Jun Zhu Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education) Department of LymphomaPeking University Cancer Hospital & Institute Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education) Department of Nuclear MedicinePeking University Cancer Hospital & Institute

Objective： diffuse large B-cell lymphoma （DLBCL） is a heterogeneous disease. The prognostic factor currently used is not accurate enough to predict the outcomes of patients with DLBCL. The prognostic significance of interim PET/CT in DLBCL remains controversial. The aim of this study is to determine the predictive value of interim 18F-FDG PET/CT after first-line treatment in patients with DLBCL. Methods： Thirty-two patients with DLBCL underwent baseline, interim and post-treatment lSF-FDG PET/CT scans. Imaging results were analyzed for the survival of patients via software SPSS 13.0, retrospectively. Results： Thirty-one of the 32 patients were treated with R-CHOP regimen, and interim 18F-FDG PET/CT of 24 patients was performed after 2 cycles of treatment. After a median follow-up period of 16.7 months, the 2-year progression-free survival （PFS） rates were significantly different between the groups above and below SUVmax CUt-Off value of 2.5 （P=0.039）. No significant differences were found in the 2-year PFS rates if SUVm, cut-offvalues were set as 2.0 and 3.0, respectively （P=0.360; P=0.113）. Conclusions： Interim PET/CT could predict the prognosis of DLBCL patients with the SUVmax cut-off value of 2.5, but more clinical data should be concluded to confirm this conclusion.

关键词： Fludeoxy-glucose F18 lyrnphoma large cell diffuse prognosis standard utility value

Prognostic Value of D-Dimer in Patients with diffuse Large B-cell Lymphoma:A Retrospective Study

在线全文

学校读者我要写书评

暂无评论

Current Medical Science 2019年第2期39卷 222-227页

作者： Yu-di GENG Yi-ren CHEN Jin JIN Xiao-di WANG Shu ZHANG Deng-ju LI Department of Hematology Tongji HospitalTongji Medical CollegeHua zhong University of Science and TechnologyWuhan 430030China College of Mathematics and Statistics Shenzhen UniversityShenzhen 518060China

This study evaluated the significance of serum D-Dimer for predicting survival of patients with diffuse large B-cell lymphoma(DLBCL).We analyzed the clinical data from 113 patients who were newly diagnosed with DLBCL at Tongji Hospital from January 2012 to January 2016.The results indicated that there were higher levels of D-Dimer in DLBCL patients with the following characteristics:stage HI/IV,lymphocyte monocyte ratio(LMR)upper limit of normal(ULN),albumin(ALB)60 years,stage m/IV,LDH>ULN,LMR0.92.Multivariate analysis showed that only LDH>ULN(P=0.038)and age>60 years(P=0.047)were independent adverse prognostic factors.However,it was suggested that D-Dimer could be regarded as a marker of high tumor burden and a potential prognostic screening tool for patients with DLBCL,not otherwise specified(NOS).

关键词： diffuse large B-cell lymphoma D-Dimer prognosis

Cardiac involvement in disseminated diffuse large B-cell lymphoma,successful management with chemotherapy dose reduction guided by cardiac imaging: A case report and review of literature

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2019年第2期7卷 191-202页

作者： Rabah Al-Mehisen Maha Al-Mohaissen Hisham Yousef Department of Cardiology Security Forces Hospital Department of Clinical Sciences (Cardiology) Princess Nourah Bint Abdulrahman University Research Chair in Cardiovascular Disease in Women Princess Nourah Bint Abdulrahman University Department of Internal Medicine Division of Hematology/Oncology Security Forces Hospital

BACKGROUND Secondary cardiac involvement by lymphoma has received limited attention in the medical literature, despite its grave prognosis. Although chemotherapy improves patients' survival, a subgroup of treated patients dies suddenly due to myocardial rupture following chemotherapy initiation. Reducing the initial chemotherapy dose with dose escalation to standard doses may be effective in minimizing this risk but the data are limited. We report on the successful management of a patient with disseminated diffuse large B-cell lymphoma(DLBCL) involving the heart using such approach.CASE SUMMARY An 18-year-old male presented to our hospital with six months history of progressive dyspnea, orthopnea and cough. On physical examination, the patient was found to have a plethoric and mildly edematous face, fixed elevation of the right internal jugular vein, suggestive of superior vena cava obstruction, and a pelvic mass. Investigations during admission including a thoracoabdominal computed tomography(CT) scan with CT guided biopsy of the pelvic mass,echocardiography and cardiac magnetic resonance imaging led to the diagnosis of disseminated DLBCL with cardiac involvement. The patients were successfully treated with chemotherapy dose reduction followed by dose escalation to standard doses, under the guidance of cardiac imaging. The patient completed chemotherapy and underwent a successful bone marrow transplant. He is currently in remission and has a normal left ventricular function.CONCLUSION Imaging-guided chemotherapy dosing may minimize the risk of myocardial rupture in cardiac lymphoma. Data are limited. Management should be individualized.

关键词： diffuse large B-cell lymphoma Cardiac lymphoma Cardiac imaging Cardiac magnetic resonance imaging Myocardial rupture Imaging-guided chemotherapy Case report

Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin:Analysis of 1,085 WHO classified cases in a single institution in China

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2019年第1期31卷 152-161页

作者： Yuankai Shi Ying Han Jianliang Yang Peng Liu Xiaohui He Changgong Zhang Shengyu Zhou Liqiang Zhou Yan Qin Yongwen Song Yueping Liu Shulian Wang Jing Jin Lin Gui Yan Sun Department of Medical Oncology Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted DrugsNational Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Departement of Radiation Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China

Objective: To explore the clinicobiologic features and outcomes of diffuse large B-cell lymphoma(DLBCL)patients in China according to the primary site.Methods: A total of 1,085 patients diagnosed with DLBCL in National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College during a 6-year period were enrolled. Their clinical characteristics and outcomes were analyzed according to the primary site.Results: In the 1,085 patients, 679(62.6%) cases were nodal DLBCL(N-DLBCL) and 406 cases(37.4%) were extranodal DLBCL(EN-DLBCL). The most common sites of N-DLBCL were lymphonodus(64.8%), Waldeyer's ring(19.7%), mediastinum(12.8%) and spleen(2.7%), while in EN-DLBCL, stomach(22.4%), intestine(16.0%),nose and sinuses(8.9%), testis(8.4%), skin(7.9%), thyroid(6.9%), central nervous system(CNS)(6.4%), breast(5.7%), bone(3.4%), and salivary gland(2.7%) were most common. N-DLBCL patients tend to present B symptoms, bulky disease, and elevated LDH more often, while age >60 years, extranodal sites >1, Ann Arbor stage I or II, bone marrow involvement, and Ki-67 index >90% were usually seen in EN-DLBCL. The 5-year overall survival(OS) rate and progression-free survival(PFS) rate for all patients were 62.5% and 54.2%. The 5-year OS rate for patients with N-DLBCL and EN-DLBCL were 65.5% and 56.9%(P=0.008), and the 5-year PFS were57.0% and 49.0%(P=0.020). Waldeyer's ring originated DLBCL possessed the highest 5-year OS rate(83.6%) and PFS rate(76.9%) in N-DLBCL. The top five EN-DLBCL subtypes with favorable prognosis were stomach,breast, nose and sinuses, lung, salivary gland, with 5-year OS rate: 70.3%, 69.6%, 69.4%, 66.7% and 63.6%,respectively. While CNS, testis, oral cavity and kidney originated EN-DLBCL faced miserable prognosis, with 5-year OS rate of 26.9%, 38.2%, and 42.9%.Conclusions: In our study, primary sites were associated with clinical characteristics and outcomes. Compared with EN-DLBCL, N-DLBCL had better prognosis.

关键词： diffuse large B-cell lymphoma(DLBCL) distribution nodal extranodal

The role of endoscopy in the management of hereditary diffuse gastric cancer syndrome

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2019年第23期25卷 2878-2886页

作者： Shria Kumar Jessica M Long Gregory G Ginsberg Bryson W Katona Division of Gastroenterology University of Pennsylvania Perelman School of MedicinePhiladelphiaPA 19104United States Division of Hematology and Oncology University of Pennsylvania Perelman School of MedicinePhiladelphiaPA 19104United States

Hereditary diffuse gastric cancer(HDGC) syndrome is an inherited cancer risk syndrome associated with path-ogenic germline CDH1 variants. Given the high risk for developing diffuse gastric cancer, CDH1 carriers are recommended to undergo prophylactic total gastrectomy for cancer risk reduction. Current guidelines recommend upper endoscopy in CDH1 carriers prior to surgery and then annually for individuals deferring prophylactic total gastrectomy.Management of individuals from HDGC families without CDH1 pathogenic variants remains less clear, and management of families with CDH1 pathogenic variants in the absence of a family history of gastric cancer is particularly problematic at present. Despite adherence to surveillance protocols, endoscopic detection of cancer foci in HDGC is suboptimal and imperfect for facilitating decision-making. Alternative endoscopic modalities, such as chromoendoscopy,endoscopic ultrasound, and other non-white light methods have been utilized,but are of limited utility to further improve cancer detection and risk stratification in HDGC. Herein, we review what is known and what remains unclear about endoscopic surveillance for HDGC, among individuals with and without germline CDH1 pathogenic variants. Ultimately, the use of endoscopy in the management of HDGC remains a challenging arena, but one in which further research to improve surveillance is crucial.

关键词： CDH1 gene Hereditary diffuse gastric cancer Gastric cancer Endoscopic screening Endoscopy

Prognostic value of ^(18)F-fluorodeoxyglucose positron emission tomography using Deauville criteria in diffuse large B cell lymphoma treated with autologous hematopoietic stem cell transplantation

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2019年第1期31卷 162-170页

作者： Zhitao Ying Lan Mi Nina Zhou Xuejuan Wang Zhi Yang Yuqin Song Xiaopei Wang Wen Zheng Ningjing Lin Meifeng Tu Yan Xie Lingyan Ping Chen Zhang Weiping Liu Lijuan Deng Jun Zhu Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of LymphomaPeking University Cancer Hospital&InstituteBeijing 100142China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Peking University Cancer Hospital&InstituteBeijing 100142China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of Nuclear MedicinePeking University Cancer Hospital&InstituteBeijing 100142China

Objective: High-dose chemotherapy(HDC) followed by autologous hematopoietic stem cell transplantation(auto-HSCT) plays an important role in improving outcomes of diffuse large B cell lymphoma(DLBCL) patients.18 F-fluorodeoxyglucose(18 F-FDG) positron emission tomography(PET)/computed tomography(CT) has been widely accepted in response assessment and prediction of prognosis in DLBCL. Here, we report the value of 18 FFDG PET/CT pre-and post-HSCT in predicting outcomes of patients with DLBCL.Methods: DLBCL patients who had PET/CT scan before and after HSCT were included. PET results were interpreted based upon Deauville criteria. The prognostic value of 18 F-FDG PET/CT in auto-HSCT was evaluated.Results: Eighty-four patients were enrolled. In univariate analysis, pre-and post-HSCT PET findings were correlated with 3-year progression-free survival(PFS) [hazard ratio(HR)=4.391, P=0.001; HR=7.607, P<0.001] and overall survival(OS)(HR=4.792, P=0.008; HR=26.138, P<0.001). Patients receiving upfront auto-HSCT after firstline treatment had better outcomes than relapsed/refractory DLBCL patients(3-year PFS, P<0.001; 3-year OS,P<0.001). In the relapsed/refractory patients, pre-and post-HSCT PET findings were also associated with 3-year PFS(P=0.003 vs. P<0.001) and OS(P=0.027 vs. P<0.001). A significant correlation was observed between clinical response to chemotherapy before auto-HSCT and outcomes of patients in the entire cohort(3-year PFS, P<0.001;3-year OS, P<0.001) and in the subgroup of 21 patients with positive pre-HSCT PET(3-year PFS, P=0.084; 3-year OS, P=0.240). A significant association between survival and post-HSCT PET findings was observed in multivariate analysis(HR=5.168, P<0.001).Conclusions: PET results before and after HSCT are useful prognostic factors for DLBCL patients receiving HSCT. Patients who responded to chemotherapy, even those with positive pre-HSCT PET, are appropriate candidates for auto-HSCT.

关键词： Positron emission tomography computed tomography autologous hematopoietic stem cell transplantation high-dose chemotherapy diffuse large B cell lymphoma